Organic Active Ingredients TRIZ Cases

Modified MTSP-1 polypeptides cleave complement protein C3, overcoming short half-lives of small molecules and immune responses to antibodies.

Segmented SDF-1 delivery recruits progenitor cells to ischemic regions, restoring left ventricular volume and ejection fraction without systemic complexity.

DNA nanoparticles integrate aptamer targeting with drug delivery, eliminating complex conjugation chemistry while enhancing binding specificity.

Vafidemstat targets the KDM1A enzyme to alleviate non-aggressive ADHD symptoms without sedative side effects.

Human milk oligosaccharides modulate gut microbiota to reduce migraine frequency, avoiding side effects of conventional treatments.

Sucralose-enhanced budesonide suspensions coat the esophagus, reducing systemic side effects while treating pediatric eosinophilic esophagitis.

Aqueous ibuprofen solution uses a solubilizing agent to maintain stability across wide concentration ranges.

Composite structures resolve the contradiction between moderate potency and lack of specificity in natural compound inhibitors.

Adding canthaxanthin and 25-hydroxy vitamin D3 to feed formulations increases rooster sperm vigor while reducing morphological defects.

Segmented biodegradable microparticles reduce ocular surface hyperemia and iris pigmentation changes while sustaining intraocular pressure control.

A nonwoven membrane of electrospun nanofibers entangles microparticles to enable sustained release of therapeutic agents.

HSP90-targeted conjugates link active agents to nanoparticles, reducing systemic toxicity and prolonging drug circulation time.

Picolinate macrocyclic ligands prevent radioelement diffusion into healthy organs by forming thermodynamically stable complexes dissolved in iodinated oils.

A magnetic patch with chelating agents removes matrix metalloproteinases, reducing tissue degeneration and promoting healing in vascular ulcers.

Targeting Cyp11A1 in CD8+ T cells resolves steroid-insensitive allergic asthma by suppressing Th2 cytokine production.

Multi-substituent psilocybin derivatives reduce adverse side effects like paranoia while enhancing therapeutic efficacy.

A biodegradable block copolymer system forms nanosystems with tunable release properties and optimized ligand-receptor stoichiometry.

Segmented glue degrader compounds modulate cereblon surface affinity to induce specific protein degradation.

Pharmaceutical pellet compositions use an organic acid core to create a localized acidic environment that enhances drug solubility and controls release kinetics.

Nested multivesicular liposomes with crosslinked carrier bilayers prevent dissipation, ensuring stable delivery of therapeutic payloads.

Optimizing the topological polar surface area to at least 145 Ų balances lung permeability against systemic absorption, extending activity duration.

Pyrazolopyrrolidine compounds inhibit gamma secretase to reduce beta amyloid peptide levels, addressing inadequate Alzheimer's disease treatments.

Structural modifications to the aromatic ring enhance central transferability while maintaining selective DP receptor binding.

Liquid plasmid DNA formulation maintains supercoiled structure using stabilizing excipients, eliminating lyophilized reconstitution complexity.

Selective reduction of indolinobenzodiazepine compounds eliminates fully reduced byproducts, removing cumbersome purification steps.

Allosteric modulation by bicyclic heteroaryl compounds increases hemoglobin S oxygen affinity, alleviating tissue oxygen deficiency in sickle cell disease.

TOFA compounds modulate hormone-sensitive lipase to treat greasy skin and hair without harsh cleansers.

Exposing pregnant females to blue light suppresses melatonin, reducing contraction frequency and delaying preterm labor onset.

Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds degrade Cyclin K to resolve selectivity and efficacy trade-offs in CDK12/13 inhibition.

Modified sulfated cellobioside neutralizes extracellular histones via electrostatic interaction, reducing cytotoxicity in sepsis.

Spirocyclic compounds selectively block the ROMK channel to reduce salt retention, avoiding hypokalemia and diuretic tolerance.

GSPT1 modulators promote premature termination codon readthrough to restore full-length protein synthesis.

Inhibiting DNA mismatch repair enzymes increases neo-antigen production, converting non-responders to immune checkpoint inhibitors into responders.

Optimizing monensin dosage to 11-14.5 g/ton resolves uncertainty in feed efficiency while maintaining stable milk fat percentages.

Periodic CHK1 inhibitor dosing after DNA damaging agents prevents repair, enhancing efficacy.

Inhibiting the Sghrt-encoded polypeptide promotes cardiomyocyte proliferation and dedifferentiation to address limited regenerative capacity in adult hearts.

Short small hairpin RNAs stabilize HIF-1α and promote angiogenesis to resolve chronic non-healing diabetic wounds.

Pyrazolopyridine compounds inhibit protein kinase C-theta to treat inflammatory and autoimmune diseases like rheumatoid arthritis.

SARD ligands degrade androgen receptor splice variants via N-terminal binding, overcoming resistance in castration-resistant prostate cancer.

Simultaneous spraying of enteric and modified release agents with pore-forming additives onto inert nuclei creates uniform pharmaceutical pellets.

Thioester prodrugs mask mercaptan groups to improve oral bioavailability, reducing gastrointestinal adverse events and oxidation in cystinuria treatment.

Combining chlorogenic acid with bifidobacteria and human milk oligosaccharides lowers bilirubin while avoiding phenobarbital toxicity.